Lindbrook Capital, LLC Zentalis Pharmaceuticals, Inc. Transaction History

Lindbrook Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$4.09 - $16.13 $552 - $2,177	135 Added 113.45%	254 $1,000
Q1 2024 Apr 25, 2024	BUY	$10.83 - $16.49 $1,288 - $1,962	119 New	119 $1,000
Q1 2023 Apr 26, 2023	BUY	$16.14 - $24.94 $6,585 - $10,175	408 Added 5100.0%	416 $7,000
Q4 2022 Jan 24, 2023	SELL	$18.07 - $25.6 $1,608 - $2,278	-89 Reduced 91.75%	8 $0
Q3 2022 Nov 10, 2022	BUY	$20.23 - $31.73 $242 - $380	12 Added 14.12%	97 $2,000
Q2 2022 Aug 01, 2022	BUY	$17.91 - $52.25 $1,522 - $4,441	85 New	85 $2,000

139

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $99.2M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.